Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.

@article{Weisbord2013PreventionOC,
  title={Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.},
  author={S. Weisbord and M. Gallagher and James L. Kaufman and A. Cass and C. Parikh and G. Chertow and K. Shunk and P. McCullough and M. Fine and Maria K. Mor and R. Lew and G. Huang and Todd A. Conner and M. Brophy and Joanne Lee and S. Soliva and P. Palevsky},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2013},
  volume={8 9},
  pages={
          1618-31
        }
}
  • S. Weisbord, M. Gallagher, +14 authors P. Palevsky
  • Published 2013
  • Medicine
  • Clinical journal of the American Society of Nephrology : CJASN
  • Contrast-induced AKI (CI-AKI) is a common condition associated with serious, adverse outcomes. CI-AKI may be preventable because its risk factors are well characterized and the timing of renal insult is commonly known in advance. Intravenous (IV) fluids and N-acetylcysteine (NAC) are two of the most widely studied preventive measures for CI-AKI. Despite a multitude of clinical trials and meta-analyses, the most effective type of IV fluid (sodium bicarbonate versus sodium chloride) and the… CONTINUE READING
    Acute kidney injury
    • 716
    Contrast‐induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies☆
    • 60
    • Highly Influenced
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 102 REFERENCES